
A Rare Flu Complication Is Killing More U.S. Children
Researchers at Stanford Medicine led the study, published Thursday in JAMA. Collecting reports from other doctors and hospitals across the country, they identified 41 cases of ANE since 2023, along with 11 deaths. The researchers argue that the condition should be systemically tracked in the U.S. from now on.
Flu Cases Are Surging—Here's Why This Season Is So Unusual
'ANE occurs when the body's immune response to influenza triggers widespread brain inflammation, particularly targeting the thalamus—a critical brain region that controls consciousness and many vital functions,' study author Keith Van Haren, a pediatric neurologist at Stanford Medicine, told Gizmodo. 'Children are disproportionately affected, possibly due to their developing immune systems and genetic factors.'
ANE is typically very rare, with Van Haren and his colleagues usually only seeing a single case every few years. But earlier this January, they came across several at their center. They also heard reports of increased cases from nearby pediatric centers in the state.
Curious, the team issued a nationwide call to infectious disease and flu specialists for any and all recent reports of ANE. All told, they documented cases from 23 hospitals dating back to October 2023. This spike is likely tied to the circulation of more severe flu strains seen during that time.
'While we can't definitively prove an increase in ANE cases, the clustering of reports and severe flu season designation suggest this may represent a genuine rise,' Van Haren said.
The median age of these cases is five years, with most involving children who had no preexisting health conditions. In addition to the 11 deaths, roughly two-thirds of children developed moderate to severe disability that was still present 90 days later. Notably, only 16% of victims were vaccinated against the flu.
The Centers for Disease Control and Prevention also received a glut of ANE reports during the recent 2024-2025 flu season. But in a February paper that examined historical data going back 15 years, CDC scientists couldn't conclusively determine whether this past season represented a real spike in cases.
Both the CDC report and the current study authors note that influenza-associated encephalopathy in general (ANE being the most severe form) isn't a nationally notifiable condition, meaning doctors aren't obligated to report cases to health departments. So if nothing else, Van Haren and his team are pushing for that to change, since better tracking would make it easier to spot rising cases moving forward. 'Typically, the U.S. CDC is best situated to undertake these efforts, which involve a high degree of collaboration across hospitals and public systems around the country,' Van Haren said.
Unfortunately, that might be easier said than done for the time being. The current Trump administration has hollowed out its public health agencies, with the CDC in particular having shed nearly one-quarter of its staff this year.
RFK Jr.'s Baseless Purge of CDC Vaccine Panel Alarms Public Health Experts
Van Haren is hopeful that clinical trials in the future will figure out which immunotherapies work best for ANE, since there's no clearly established optimal treatment as of yet. And dire as the overall public health situation is, there is something we can all do to further lower the rare danger of ANE: Get the seasonal flu vaccine.
'The most important message is prevention: seasonal influenza vaccination significantly reduces the risk of severe complications like ANE,' Van Haren said. 'Parents should ensure their children receive annual flu vaccines and seek immediate medical attention for any child with flu symptoms who develops altered mental status, seizures, or severe neurological changes.'
For now, at least, the White House hasn't directly gone after the flu shot, though Health Secretary RFK Jr. did recently sign off on removing a small minority of flu vaccines containing thimerosal, an ingredient antivaxxers have long and wrongly blamed for causing autism.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at To participate via telephone, please dial 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) and use conference ID number 10201618. An archive of the audio webcast will be available on Atea's website approximately two hours after the conference call and will remain available for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea's lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company's plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including 'may,' 'will,' 'anticipates,' 'plans,' and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption 'Risk Factors' in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC's website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contacts Jonae BarnesSVP, Investor Relations and Corporate Joyce AllaireLifeSci AdvisorsJallaire@
Yahoo
24 minutes ago
- Yahoo
ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering
ST. PAUL, Minn., July 31, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that three investigators at the University of Minnesota's Center for Genome Engineering have been awarded $665,000 of G-Rex® Grant funding. Dr. Branden Moriarity, Associate Professor at the University of Minnesota, Co-Director of Center for Genome Engineering, Co-Director of the Genome Engineering Shared Resource, and Member of the Masonic Cancer Center, was awarded a $300,000 G-Rex Grant to support technology transfer, process development and qualification runs for a novel hyper-functional Chimeric Antigen Receptor (CAR) Natural Killer (NK) cell therapy for the treatment of advanced epithelial ovarian cancer (EOC) in a Phase 1 clinical trial. Dr. Beau Webber, Associate Professor at the University of Minnesota, Co-Director of the Genome Engineering Shared Resource, Member of the Center for Genome Engineering, and Member of the Masonic Cancer Center, was awarded a $240,000 G-Rex Grant to support preclinical development of a novel tumor infiltrating lymphocyte (TIL) therapy for the treatment of various solid tumors. Dr. Joseph Skeate, Assistant Professor at the University of Minnesota, was awarded a $125,000 G-Rex Grant to support process development and optimization of a G-Rex® centric manufacturing processes for production of a TPP1 expressing T cells therapy for the treatment of Batten Disease, a group of rare, inherited neurodegenerative disorders that typically begin in childhood. "We are highly appreciative of receiving significant G-Rex Grant funding that will improve G-Rex centric manufacturing for our unique cell and gene therapy drug products. The willingness of our Minnesota neighbors, Wilson Wolf and Bio-Techne, to allocate financial resources to our University of Minnesota cell and gene therapy (CGT) programs and the CGT field as a whole is greatly appreciated," said Dr. Branden Moriarity. "The state of Minnesota has a long history of pioneering adoptive cell therapy efforts dating back to 1968 when the first bone marrow transplant with a matched related donor occurred at the University of Minnesota. It's our pleasure to award G-Rex Grant funds to these leading investigators at the Center for Genome Engineering to advance their diverse portfolio of innovate cell therapies for devastating cancers and rare diseases and we are fortunate to be able to play a small role in supporting Minnesota's contributions to the field of Cell & Gene Therapy," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. View original content to download multimedia: SOURCE Bio-Techne Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Cigna Group shares rise as Q2 results top estimates
-- The Cigna (NYSE:CI) Group reported better-than-expected second quarter 2025 results on Wednesday, as strong growth in its Evernorth Health Services segment drove revenue significantly higher. Shares rose 1% following the announcement. The health services company posted adjusted earnings of $7.20 per share, exceeding analyst expectations of $7.16. Revenue surged 11% YoY to $67.2 billion, well above the consensus estimate of $62.66 billion. The company reaffirmed its full-year 2025 adjusted earnings outlook of at least $29.60 per share, slightly below analyst projections of $29.69. Evernorth Health Services, which includes pharmacy benefit management and specialty pharmacy services, was the primary growth driver with adjusted revenues increasing 17% to $57.8 billion compared to the same period last year. The segment's pre-tax adjusted income rose 5% to $1.7 billion. "Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value," said David M. Cordani, chairman and CEO of The Cigna Group. "Our performance in the second quarter reflects our disciplined execution and the strength of our business mix." The Cigna Healthcare segment saw adjusted revenues decrease 18% to $10.8 billion, primarily due to the divestiture of its Medicare businesses to Health Care Services Corporation in March 2025. Excluding this transaction, the segment's revenue would have increased 7% YoY. The company's medical care ratio rose to 83.2% from 82.3% in the year-ago quarter, reflecting expected higher stop loss medical costs. Total pharmacy customers increased 3% from December 31, 2024, to 121.9 million, while total medical customers decreased 6% to 18 million, primarily due to the HCSC transaction. Related articles Cigna Group shares rise as Q2 results top estimates These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Surge of 50% since our AI selection, this chip giant still has great potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data